Somatostatin - Pharmbio Korea
Latest Information Update: 10 Sep 2016
At a glance
- Originator Pharmbio Korea
- Class Antihaemorrhagics; Antineoplastics; Cyclic peptides; Pancreatic hormones; Pituitary hormone release inhibiting hormones
- Mechanism of Action Corticotropin-releasing factor antagonists; Growth hormone releasing factor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Liver failure